Ose Pharma SA (OSEPharma)

Oncology Corporate Profile

HQ Location

22, boulevard Benoni Goullin
44200 Nantes, France 75014

Company Description

OSE Pharma is a European cancer immunotherapy company with a specific T cytotoxic technology, focused on developing multi-epitopes therapeutic cancer vaccines. OSE Pharma's lead product, OSE-2101 is about to enter a pivotal Phase 3 study in patients with non small cell lung cancer (NSCLC), is ready for Phase 2 development in other cancer indications (ovarian, colon, breast, prostate) and is a suitable candidate for immune combination therapy. OSE-2101 targets five tumor associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. OSE-2101 contains ten optimized epitopes, derived from these five tumor antigens, which generate strong specific T cytotoxic responses that lead to the body's immune system killing tumor cells expressing the tumor antigens.

Website: http://www.osepharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
OSE2101immunotherapyNon Small Cell Lung Cancer (NSCLC)III
OSE2101immunotherapyBreast cancerII
OSE2101immunotherapyColorectal cancerII
OSE2101immunotherapyOvarianII

Source: http://www.osepharma.com

Recent News Headlines

There are no news items to display